Easily accessible TADDOL-derived bisphosphonite ligands: Synthesis and application in the asymmetric hydroformylation of vinylarenes

Advanced Synthesis and Catalysis

Volumn 357, Issue 1, 2015, Pages 41-45

  Allmendinger, Simon ^a   Kinuta, Hirotaka ^a   Breit, Bernhard ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Aldehydes; Asymmetric catalysis; Hydroformylation; Ligand design; P ligands; Rhodium

Indexed keywords

EID: 84920807411     PISSN: 16154150     EISSN: 16154169     Source Type: Journal    
DOI: 10.1002/adsc.201400657     Document Type: Article

References (32)

1. a) Rhodium Catalyzed Hydroformylation, Vol. 22, (Eds.: P. W. N. M. Van Leeuwen, C. Claver), Kluwer Academic Publishers, Dordrecht, 2000;
2. b) B. Breit, W. Seiche, Synthesis 2001, 1-36;
3. c) B. Breit, Angew. Chem. 2005, 117, 6976-6986;
4. Angew. Chem. Int. Ed. 2005, 44, 6816-6825;
5. d) R. Franke, D. Selent, A. Börner, Chem. Rev. 2012, 112, 5675-5732.
6. a) F. Agbossou, J. F. Carpentier, A. Mortreaux, Chem. Rev. 1995, 95, 2485-2506;
7. b) C. Claver, P. W. N. M. Van Leeuwen, in: Rhodium Catalyzed Hydroformylation, Vol. 22, (Eds.: P. W. N. M. Van Leeuwen, C. Claver), Kluwer Academic Publishers, Dordrecht, 2000, pp 107-124;
8. c) M. Diéguez, O. Pàmies, C. Claver, Tetrahedron: Asymmetry 2004, 15, 2113-2122;
9. d) C. Claver, M. Diéguez, O. Pàmies, S. Castillón, Top. Organomet. Chem. 2006, 18, 35-64;
10. e) J. Klosin, C. R. Landis, Acc. Chem. Res. 2007, 40, 1251-1259;
11. f) S. H. Chikkali, J. I. van der Vlugt, J. N. H. Reek, Coord. Chem. Rev. 2014, 262, 1-15.
12. a) C. Botteghi, S. Paganelli, A. Schionato, M. Marchetti, Chirality 1991, 3, 355-369;
13. b) S. Ho, C. Bucher, J. L. Leighton, Angew. Chem. Int. Ed. 2013, 52, 6757-6761;
14. c) R. M. Risi, S. D. Burke, Org. Lett. 2012, 14, 1180-1182;
15. d) R. M. Risi, S. D. Burke, Org. Lett. 2012, 14, 2572-2575;
16. e) B. Breit, A. Bigot, Chem. Commun. 2008, 6498-6500.
17. N. Sakai, S. Mano, K. Nozaki, H. Takaya, J. Am. Chem. Soc. 1993, 115, 7033-7034.
18. a) Y. J. Yan, X. M. Zhang, J. Am. Chem. Soc. 2006, 128, 7198-7202;
19. b) X. W. Zhang, B. N. Cao, Y. J. Yan, S. C. Yu, B. M. Ji, X. M. Zhang, Chem. Eur. J. 2010, 16, 871-877.
20. G. M. Noonan, C. J. Cobley, T. Mahoney, M. L. Clarke, Chem. Commun. 2014, 50, 1475-1477.
21. M. Dieguez, O. Pamies, A. Ruiz, S. Castillon, C. Claver, Chem. Commun. 2000, 1607-1608.
22. a) T. P. Clark, C. R. Landis, S. L. Freed, J. Klosin, K. A. Abboud, J. Am. Chem. Soc. 2005, 127, 5040-5042;
23. b) A. L. Watkins, B. G. Hashiguchi, C. R. Landis, Org. Lett. 2008, 10, 4553-4556.
24. D. Seebach, A. K. Beck, A. Heckel, Angew. Chem. 2001, 113, 96-142;
25. Angew. Chem. Int. Ed. 2001, 40, 92-138.
26. B. Zhao, X. Peng, Z. Wang, C. Xia, K. Ding, Chem. Eur. J. 2008, 14, 7847-7857.
27. a) T. Robert, Z. Abiri, J. Wassenaar, A. J. Sandee, S. Romanski, J. M. Neudörfl, H. G. Schmalz, J. N. H. Reek, Organometallics 2010, 29, 478-483;
28. b) J. Wassenaar, B. de Bruin, J. N. H. Reek, Organometallics 2010, 29, 2767-2776.
29. 4 are generated as side products. Due to the presence of this acid, the enantioselectivity is most likely to be degraded by acid-catalyzed racemization.
30. Purifying the aldehyde via chromatography caused a deterioration of the optical purity (65% ee).
31. D of the isolated acids indicated that virtually no racemization occurred during oxidation.
32. Exclusively the (S)-enantiomer of Naproxen is actually approved as a drug. Employing the opposite enantiomer of ligand 11a will provide the correct configuration.